期刊文献+

药学干预在促进喹诺酮类药物合理使用中的作用分析 被引量:15

Pharmaceutical Intervention in Promoting the Role of Quinolones Reasonable Use Analysis
下载PDF
导出
摘要 目的探讨药学干预在促进喹诺酮类药物合理使用中的作用,并评估其效果。方法对该院喹诺酮类药物处方的合理性使用实施药学干预模式,并评估其干预前后的效果。结果医院的喹诺酮类药物的使用效果显著提高,药学干预后该院分离的革兰阴性菌如铜铝假单细胞菌、大肠埃希菌以及肺炎克雷伯菌对喹诺酮类药物的耐药性明显降低,差异具有统计学意义(P<0.05)。经药学干预后,该院喹诺酮类药物不合理使用处方量与干预前相比明显下降,差异具有统计学意义(P<0.05)。其中严重问题降低到0,重要问题和一般问题下降的趋势也比较明显,差异具有统计学意义(P<0.05)。药学干预后,该院喹诺酮类药物不合理用法以及用量与干预前相比明显的下降,差异具有统计学意义(P<0.05)。不合理联合用药的情况与干预前相比出现明显改善,差异具有统计学意义(P<0.05)。结论药学干预可以有效地促进喹诺酮类药物合理使用,降低药物的耐药性发生率,具有良好的效果。 Objective To investigate the effect of pharmaceutical intervention in promoting the rational use of quinolones,and evaluate its effect. Methods The implementation of pharmacy intervention rational use of quinolones prescriptions in our hospital, and to evaluate the effects before and after intervention. Results The medical use of quinolones effect significantly improved after intervention in our hospital pharmacy, such as drug resistance separation leather reduce copper Pseudomonas aeruginosa and Escherichia coli and Klebsiella pneumoniae to quinolones were Gram-negative bacteria the difference was statistically significant(P〈0.05). The pharmaceutical intervention, unreasonable use of prescription and intervention of quinolones in our hospital than before significantly decreased the difference was statistically significant(P〈0.05). The serious problem is reduced to 0, the important problem and the general problem of the trend is also more obvious the difference has statistical significance(P〈0.05). Pharmaceutical intervention of quinolones in our hospital is reasonable usage and dosage compared with before intervention decreased significantly the difference was statistically significant(P〈0.05). The situation of irrational combined use of drugs was significantly improved compared with that before intervention the difference was statistically significant(P〈0.05). Conclusion pharmaceutical intervention can effectively promote the rational use of quinolones, reduce the incidence of drug resistance, has a good effect.
作者 李冠军
出处 《中国卫生产业》 2015年第29期21-23,共3页 China Health Industry
关键词 药学干预 喹诺酮类药物 合理使用 作用 分析 Pharmaceutical intervention Quinolones Rational use Effect Analysis
  • 相关文献

参考文献7

二级参考文献56

  • 1唐双意,陈龙英,杨玉芳,刘滔滔,钟小斌.369例喹诺酮类药物不良反应分析[J].中国医院药学杂志,2006,26(3):364-365. 被引量:21
  • 2邹豪,邵元福,朱才娟,邓渝林,马玉杰,陈盛新.医院药品DDD数排序分析的原理及利用[J].中国药房,1996,7(5):215-217. 被引量:1426
  • 3康维明,赵玉沛.氟喹诺酮类抗菌药在外科系统感染预防及治疗中的合理应用[J].中国社区医师,2006,22(8):23-24. 被引量:4
  • 4中华人民共和国卫生部.关于抗菌药物临床应用管理有关问题的通知[S] ,卫办医政发(2009)38号,2009.
  • 5陈晓琪,臧益秀,现代临床合理用药[M].济南:山东科学技术出版社.2002.135.
  • 6冯丽萍,党丽娟.2006年广东省喹诺酮类药品不良反应分析[J].广东药学院学报,2007,23(5):556-558. 被引量:22
  • 7Sendzik J, Shakibaei M, Schfifer-Korting M, et al. Syner- gistic effects of dexamethasone and quinolones on human derived tendon cells[J]. Int J Antimicrob Agents,2010,35 (4) :366-374.
  • 8Bennett DE, Bertagnolio S, Sutherland D, et al. The World Health O.Yganizationrs global strategy for prevention and assessment of HIV drug resistance [J]. Antivir Ther, 2008,13(Suppl 2) :S1- 13.
  • 9Fong DT,Pang KY,Chung MM,et al. Evaltlation of corn bined prescription of rocker sole shoes and custom-made foot orthoses for the treatment of plantar faseiitis[J]. Clin Biomech (Bristol,Avon) ,2012,27(10) :1072-1077.
  • 10Hassani Y, Hochart C, Hassani I., et al. Monitoring and evaluation tools for irinotecan and bevacizumab in glio- blastoma: from prescription to patient' s information[J]. Bull Cancer,2012,99(5) :513-520.

共引文献116

同被引文献59

  • 1P6rez-Moreno MO, Pic6-Plana E, de Toro M,et al.13-Lacta- mases,transferable quinolone resistance determinants,and class 1 integron-mediated antimicrobial resistance in hu- man clinical Salmonella enterica isolates of non-Typhimuri- um serotypes[J].Int Med Microbiol, 2013,303 (1) : 25-31.
  • 2Campos MJ,Palomo G,Hormeo L,et d~Prevalence of quinolone resistance determinants in non-typhoidal Salmonella isolates from human origin in Extremadura, Spain[J].Diagn Microbiol Infect Dis, 2014,79 (1) : 64-69.
  • 3段华.药学干预对喹诺酮类药物使用情况的影响探讨[J].医药前沿,2013,3(18):194-195.
  • 4谢健敏.药学干预对喹诺酮类药物使用情况的影响探讨[J].医药前沿.2013.3(15):19-20.
  • 5Kim KY,Park JH,Kwak HS,et a/.Characterization of the quinolone resistance mechanism in foodborne Salmonella isolates with high nalidixic acid resistance[J].Int J Food Microbiol, 2011,146( 1 ) : 52-56.
  • 6陆芳.喹诺酮类药物使用情况的药学干预分析[J].医药前沿,2014,4(11):115.
  • 7韩圣良.研究药学干预对喹诺酮类药物使用情况的影响[J].中外健康文摘,2014,11(24):89.
  • 8Liu YH, Kuo SC,Lee YT,et a/.Amino acid substitutions of quinolone resistance determining regions in GyrA and ParC associated with quinolone resistance in Acinetobacter bauma~nii and Acinetobacter genomic species 13TU[J].J Microbiol, 2012,45 (2) : 108-112.
  • 9陈曼,吴文渊.喹诺酮类药物在抗结核病治疗中合理使用MTP干预的研究[J].中国现代医生,2010,48(23):134-135. 被引量:5
  • 10范秀英,刘洪峰.药学干预前后我院住院患者氟喹诺酮类应用情况分析[J].安徽医药,2011,15(5):646-648. 被引量:24

二级引证文献60

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部